Healixia symposium: Strengthening the landscape for Early Phase clinical studies in Belgium
Schedule of Healixia symposium: Strengthening the landscape for Early Phase clinical studies in Belgium
| On Friday 4 October: | |
| 13:00 - 13:15 | Registration |
| 13:15 - 13:30 | Welcome & introduction with pre-symposium survey results |
| 13:30 - 14:05 | The impact of EU-CTR on clinical vaccine research in Belgium by Isabel Leroux-Roels (UZ Gent) |
| Early phase studies with genetically modified (GMO) vaccines, a case study by Bruno Speder (AstriVax) | |
| 14:05 - 14:40 | Early phase achievements & proposed improvements from regulatory perspective by Katelijne Anciaux (CT College) |
| How to consolidate Belgium as an early clinical trial hub: challenges and opportunities in an evolving landscape by Nathalie Lambot (pharma.be) | |
| 14:40 - 15:00 | Panel discussion |
| 15:00 - 15:30 | Coffee break |
| 15:30 - 15:50 | Modus operandus and role of BAREC in the Belgian landscape by Pieter Moons (BAREC) |
| 15:50 - 16:30 | Data transparancy rules from regulatory perspective by Nele Steens (FAMHP) |
| EU Clinical Trial Regulation and Data Transparency: Implications for protecting our Innovation by Maarten Timmers (Johnson & Johnson) | |
| Panel discussion | |
| 16:30 - 16:50 | CTR and academic research by Minne Casteels & Ruth Storme (KU Leuven) |
| 16:50 - 17:00 | Symposium wrap-up |
| 17:00 - 18:00 | Closing drink |